Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence.


Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
01 05 2023
Historique:
medline: 3 5 2023
pubmed: 10 2 2023
entrez: 9 2 2023
Statut: epublish

Résumé

Adult granulosa cell tumors represent less than 5% of all ovarian malignancies. The aim of this study was to analyze the clinicopathological parameters and their impact on progression-free and overall survival. Patients with primary adult granulosa cell tumors treated in three international referral centers between July 1999 and December 2018 were included. The following data were anonymously exported from the prospective database: age at diagnosis, International Federation of Gynecology and Obstetrics (FIGO) stage, adjuvant therapy, surgical procedures, progression-free survival, and overall survival. Descriptive statistical analysis regarding tumor and treatment characteristics was performed. Survival analyses included Kaplan-Meier functions and Cox proportional hazard ratios (HR). A total of 168 patients with primary adult granulosa cell tumors were included. Median age was 50 years (range 13-82). With regard to stage distribution, 54.2% (n=91) of patients were FIGO stage IA, 1.2% (n=2) were stage IB, 26.8% (n=45) were stage IC, and 17.9% (n=30) were FIGO stage II-IV. 66.7% (n=112) of patients underwent surgical restaging, of whom 17.9% (n=20) were moved to a higher stage. In addition, 36 (21.4%) patients underwent fertility-sparing surgery. After a median follow-up of 61 months (range 0-209), 10.7% of patients (n=18) had recurrent disease and 4.8% (n=8) died of disease. Five-year progression-free survival was 86.1% and estimated overall survival was 95.7%. Five-year progression-free survival was worse for patients with advanced stages (FIGO stage IA/B vs IC: HR 5.09 (95% CI 1.53 to 16.9); FIGO stage IA/B vs II-IV: HR 5.62 (95% CI 1.58 to 19.9)). Nineteen patients receiving adjuvant chemotherapy had lower estimated 5-year progression-free survival compared with patients not receiving chemotherapy (49.7% vs 91.1%, p<0.001; HR 9.15 (95% CI 3.62 to 23.1)). The prognosis of patients with primary adult granulosa cell tumors is mainly determined by FIGO stage. The outcome of patients with FIGO stage IC is comparable to those with advanced stages. Fertility-sparing surgery seems to be a safe procedure in stage IA. Our data do not support the use of adjuvant chemotherapy in early and advanced stages of adult granulosa cell tumors.

Identifiants

pubmed: 36759002
pii: ijgc-2022-003854
doi: 10.1136/ijgc-2022-003854
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

734-740

Informations de copyright

© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Helmut Plett (H)

Department of Gynecology, University Hospital Leipzig, Leipzig, Germany pletth@googlemail.com.
Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany.
Department of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin, Berlin, Germany.

Enzo Ricciardi (E)

Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Ospedale Sandro Pertini, Rome, Italy.
Department of Gynecology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Vlad Vacaru (V)

Department of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin, Berlin, Germany.
Division of Gynecology, Vivantes Humboldt-Klinikum, Berlin, Germany.

Jan Philipp Ramspott (JP)

Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany.
Department of General, Visceral and Transplant Surgery, University Hospital Münster, Münster, Germany.

Nicoletta Colombo (N)

Department of Gynecology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
Faculty of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.

Jalid Sehouli (J)

Department of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin, Berlin, Germany.

Andreas du Bois (A)

Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany.

Annalisa Garbi (A)

Department of Gynecology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Rolf Richter (R)

Department of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin, Berlin, Germany.

Beyhan Ataseven (B)

Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany.
Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.

Giovanni Aletti (G)

Department of Gynecology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.

Elena Braicu (E)

Department of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin, Berlin, Germany.

Florian Heitz (F)

Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany.
Department of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin, Berlin, Germany.

Rosalba Portuesi (R)

Department of Gynecology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
IRCCS, Humanitas Research Hospital, Rozzano, Milan, Italy.

Mustafa-Zelal Muallem (MZ)

Department of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin, Berlin, Germany.
Berlin Institute of Health, Berlin, Virchow Campus Clinic, Charité Medical University, Berlin, Germany.

Timoleon Dagres (T)

Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany.

Gabriella Parma (G)

Department of Gynecology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Eva Roser (E)

Department of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin, Berlin, Germany.

Alexander Traut (A)

Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany.

Francesco Multinu (F)

Department of Gynecology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Philipp Harter (P)

Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH